Plus Therapeutics Strengthens Clinical Program with the Appointment of Pius Maliakal as Vice President of Clinical Operations
27 Juillet 2023 - 10:05PM
Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a
clinical-stage pharmaceutical company developing targeted
radiotherapeutics with advanced platform technologies for central
nervous system cancers, today announced the appointment of Pius
Maliakal, M. Pharm., Ph.D., as Vice President of Clinical
Operations. Dr. Maliakal will be responsible for the strategy and
planning of key clinical operational initiatives, focusing on
advancing the Company’s lead clinical trials, ReSPECT-GBM and
ReSPECT-LM, and further developing the broader pipeline.
Dr. Maliakal is an accomplished R&D
professional who brings over 20 years of global and domestic
experience to Plus Therapeutics. Prior to joining the Company, he
served as Director of Clinical Science at PTC Therapeutics, leading
the clinical development, clinical trial operations, strategies,
and data interpretations of all oncology assets across the
enterprise. Previously, as Director of Clinical Development at
Eagle Therapeutics, he led and facilitated the core design and
conduct of Phase 1 and 2 clinical trials within breast cancer, lung
cancer and other solid tumors. During his prior tenure at
Immunomedics, he was instrumental in the Phase 1 through Phase 3
clinical trials of Trodelvy (sacituzumab govitecan) leading to
accelerated FDA approval for treatment of triple-negative breast
cancer as well as other investigational agents, including unesbulin
and emvododstat. Dr. Maliakal earned his M. Pharm. from Nagpur
University, India and his Ph.D. from the University of Otago, New
Zealand.
“Pius has a unique blend of experience in
oncologic clinical development and trial operations that will make
an immediate positive impact to our team,” said Marc Hedrick, M.D.,
President and Chief Executive Officer. “As we move our co-lead
programs in glioblastoma and leptomeningeal metastases to the next
clinical stages, our clinical operational team also needs to expand
and advance. We are confident in Pius’ track record of clinical
leadership, successful regulatory submissions, early- to late-stage
trial preparation and execution with novel investigational
therapeutics.”
Dr. Maliakal added, “I’m excited to be joining
the team at such an important time, and I’m eager to contribute my
expertise to support ongoing pipeline development and generate a
long-term clinical strategy within the Company. Based on the
Company’s promising data readouts in both glioblastoma and
leptomeningeal metastases, PLUS has tremendous potential to help
patients with central nervous system cancers.”
About Plus TherapeuticsPlus
Therapeutics, Inc. is a clinical-stage pharmaceutical company
developing targeted radiotherapeutics for difficult-to-treat
cancers of the central nervous system with the potential to enhance
clinical outcomes for patients. Combining image-guided local beta
radiation and targeted drug delivery approaches, the Company is
advancing a pipeline of product candidates with lead programs in
recurrent glioblastoma (GBM) and leptomeningeal metastases (LM).
The Company has built a robust supply chain through strategic
partnerships that enable the development, manufacturing and future
potential commercialization of its products. Plus Therapeutics is
led by an experienced and dedicated leadership team and has
operations in key cancer clinical development hubs including Austin
and San Antonio, Texas. For more information, visit
https://plustherapeutics.com/.
Cautionary Statement Regarding
Forward-Looking StatementsThis press release contains
statements that may be deemed “forward-looking statements” within
the meaning of U.S. securities laws. All statements in this press
release other than statements of historical fact are
forward-looking statements. These forward-looking statements may be
identified by future verbs, as well as terms such as “designed to,”
“will,” “can,” “potential,” “focus,” “preparing,” “next steps,”
“possibly,” and similar expressions or the negatives thereof. Such
statements are based upon certain assumptions and assessments made
by management in light of their experience and their perception of
historical trends, current conditions, expected future developments
and other factors they believe to be appropriate. These statements
include, without limitation, statements regarding the following:
the potential promise of 186Re including the ability of 186Re to
safely and effectively deliver radiation directly to the tumor at
high doses; expectations as to the Company’s future performance
including the next steps in developing the Company’s current
assets; the Company’s clinical trials including statements
regarding the timing and characteristics of the ReSPECT-GBM and
ReSPECT-LM clinical trials; possible negative effects of 186Re; the
continued evaluation of 186Re including through evaluations in
additional patient cohorts; and the intended functions of the
Company’s platform and expected benefits from such functions.
The forward-looking statements included in this
press release are subject to a number of risks and uncertainties
that may cause actual results to differ materially from those
discussed in such forward-looking statements. These risks and
uncertainties include, but are not limited to: the Company’s actual
results may differ, including materially, from those anticipated in
these forward-looking statements as a result of various factors,
including, but not limited to, the following: the early stage of
the Company’s product candidates and therapies, the results of the
Company’s research and development activities, including
uncertainties relating to the clinical trials of its product
candidates and therapies; the Company’s liquidity and capital
resources and its ability to raise additional cash, the outcome of
the Company’s partnering/licensing efforts, risks associated with
laws or regulatory requirements applicable to it, market
conditions, product performance, litigation or potential
litigation, and competition within the cancer diagnostics and
therapeutics field, among others; and additional risks described
under the heading “Risk Factors” in the Company’s Securities and
Exchange Commission filings, including in the Company’s annual and
quarterly reports. There may be events in the future that the
Company is unable to predict, or over which it has no control, and
its business, financial condition, results of operations and
prospects may change in the future. The Company assumes no
responsibility to update or revise any forward-looking statements
to reflect events, trends or circumstances after the date they are
made unless the Company has an obligation under U.S. federal
securities laws to do so.
Investor ContactPeter VozzoICR Westwicke(443)
377-4767Peter.Vozzo@westwicke.com
Media ContactTerri ClevengerICR Westwicke(203)
856-4326Terri.Clevenger@westwicke.com
Plus Therapeutics (NASDAQ:PSTV)
Graphique Historique de l'Action
De Août 2024 à Sept 2024
Plus Therapeutics (NASDAQ:PSTV)
Graphique Historique de l'Action
De Sept 2023 à Sept 2024